Annovis Bio closed a $6 million stock offering for developing therapies for neurodegenerative diseases.
Quiver AI Summary
Annovis Bio, Inc. announced the successful closing of its registered direct offering, selling 4,000,000 shares of common stock at $1.50 per share, generating approximately $6 million in gross proceeds. The funds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for this offering, which was conducted under a previously filed registration statement with the SEC. The press release emphasizes that it does not constitute an offer or solicitation to sell securities in jurisdictions where such actions would be unlawful. Annovis, based in Malvern, Pennsylvania, focuses on developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Potential Positives
- Company successfully closed a registered direct offering, raising approximately $6 million in gross proceeds, which can enhance its financial stability.
- The funds from the offering will be used toward working capital and general corporate purposes, indicating a strategic focus on operational growth and development.
- The offering reflects investor confidence in Annovis Bio’s commitment to developing transformative therapies for serious neurodegenerative diseases.
Potential Negatives
- The offering price of $1.50 per share may indicate weak investor confidence, as it suggests the company may not be able to attract sufficient investment at a higher valuation.
- The company raised only $6 million, which might not be sufficient to support its intended projects and operations, potentially limiting its capacity to develop therapies for neurodegenerative diseases.
- The mention of risks and uncertainties in the forward-looking statements highlights potential volatility and challenges that could affect investor sentiment and stock performance.
FAQ
What was the recent offering by Annovis Bio?
Annovis Bio closed a registered direct offering of 4,000,000 shares of common stock at $1.50 per share.
How much gross proceeds did Annovis Bio raise?
The gross proceeds from the offering were approximately $6 million before deducting fees and expenses.
What will the proceeds from the offering be used for?
The net proceeds will be allocated towards working capital and general corporate purposes.
Who acted as the placement agent for the offering?
H.C. Wainwright & Co. served as the exclusive placement agent for the stock offering.
Where can I find more information about Annovis Bio?
For more information, visit Annovis Bio's website at www.annovisbio.com or follow them on social media.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANVS Hedge Fund Activity
We have seen 21 institutional investors add shares of $ANVS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP removed 166,219 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $360,695
- UBS GROUP AG removed 134,559 shares (-83.6%) from their portfolio in Q2 2025, for an estimated $291,993
- TWO SIGMA ADVISERS, LP removed 92,921 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $201,638
- MARSHALL WACE, LLP added 90,907 shares (+inf%) to their portfolio in Q2 2025, for an estimated $197,268
- VANGUARD GROUP INC added 48,844 shares (+7.5%) to their portfolio in Q2 2025, for an estimated $105,991
- WARBERG ASSET MANAGEMENT LLC removed 39,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $84,630
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 36,853 shares (+28.9%) to their portfolio in Q2 2025, for an estimated $79,971
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANVS Analyst Ratings
Wall Street analysts have issued reports on $ANVS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for $ANVS, check out Quiver Quantitative's $ANVS forecast page.
$ANVS Price Targets
Multiple analysts have issued price targets for $ANVS recently. We have seen 2 analysts offer price targets for $ANVS in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Sumant Kulkarni from Canaccord Genuity set a target price of $17.0 on 09/30/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $10.0 on 09/03/2025
Full Release
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering were approximately $6 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.
The securities described above were offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
[email protected]
